PCVX Vaxcyte, Inc.
Company Analysis
Latest News
Vaxcyte reports third quarter 2026 results with $3.4B pro forma cash following positive VAX-31 Phase 3 data
Vaxcyte reported a net loss for the third quarter of 2026 as it accelerated clinical development and manufacturing scale-up for its lead vaccine candidate,...
Vaxcyte Inc Q3 2026 Earnings Preview: What Analysts Expect on November 03, 2026
Vaxcyte is expected to post a Q3 2026 loss of $1.84 per share on revenue of $12.50 million, while its current share price of $62.61 trades at a significant...
Vaxcyte Closes Over $1.1 Billion in Concurrent Equity and Convertible Note Offerings
Vaxcyte, Inc. (PCVX) announced the closing of its concurrent public offerings of common stock, pre-funded warrants, and convertible senior notes, raising...
Vaxcyte Reports Positive Phase 3 Topline Data for VAX-31 Vaccine Candidate
Vaxcyte announced positive topline results from its OPUS-1 pivotal Phase 3 trial for VAX-31, its 31-valent pneumococcal conjugate vaccine (PCV) candidate. The...
Vaxcyte Appoints New CMO and CLO, Narrows VAX-31 Pivotal Trial Data Timeline
Vaxcyte announced the appointment of a new Chief Medical Officer and Chief Legal Officer, strengthening its leadership team ahead of key clinical data. The...
Farallon Capital Exits $73M Stake in Vaccine Developer Vaxcyte (PCVX)
Farallon Capital Management sold its entire position in Vaxcyte Inc. (PCVX), a clinical-stage vaccine company, during the second quarter of 2026. The major...
Seth Klarman's Baupost Group Exits Vaxcyte (PCVX) Stake
Seth Klarman's Baupost Group sold its entire stake in Vaxcyte (PCVX), a clinical-stage vaccine company, during the second quarter of 2026. The influential...